AOXG (Aoxing Pharmaceutical Co) Altman Z-Score: -0.87 (As of Jul. 03, 2026)


What is Aoxing Pharmaceutical Co Altman Z-Score?

Aoxing Pharmaceutical Co AOXG Altman Z-Score is -0.87 as of Jul. 03, 2026.

The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.

Aoxing Pharmaceutical Co has a Altman Z-Score of -0.87, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.

The historical rank and industry rank for Aoxing Pharmaceutical Co's Altman Z-Score or its related term are showing as below:


Aoxing Pharmaceutical Co  (OTCPK:AOXG) Altman Z-Score Explanation

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.

X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.

Read more about Altman Z-Score and the original research.


Be Aware

Altman Z-Score does not apply to financial companies.


Aoxing Pharmaceutical Co Altman Z-Score Related Terms


Aoxing Pharmaceutical Co Altman Z-Score Historical Data

* Premium members only.

The historical data trend for Aoxing Pharmaceutical Co's Altman Z-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aoxing Pharmaceutical Co Altman Z-Score Chart

Aoxing Pharmaceutical Co Annual Data
Trend Jun07 Jun08 Jun09 Jun10 Jun11 Jun12 Jun13 Jun14 Jun15 Jun16
Altman Z-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.87 -2.98 -2.81 0.79 0.11

Aoxing Pharmaceutical Co Quarterly Data
Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17
Altman Z-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 0.11 -0.08 -0.55 -0.47

AOXG vs OWCP, BSPK, MYHI: Altman Z-Score Comparison

For the Shell Companies subindustry, Aoxing Pharmaceutical Co's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aoxing Pharmaceutical Co Altman Z-Score vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Aoxing Pharmaceutical Co's Altman Z-Score distribution charts can be found below:

* The bar in red indicates where Aoxing Pharmaceutical Co's Altman Z-Score falls into.



Aoxing Pharmaceutical Co Altman Z-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Aoxing Pharmaceutical Co's Altman Z-Score for today is calculated with this formula:

Z=1.2*X1+1.4*X2+3.3*X3+0.6*X4+1.0*X5
=1.2*-0.1468+1.4*-0.8942+3.3*0.0164+0.6*0.0352+1.0*0.4819
=-0.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.

Trailing Twelve Months (TTM) ended in Mar. 2017:
Total Assets was $62.47 Mil.
Total Current Assets was $34.80 Mil.
Total Current Liabilities was $43.97 Mil.
Retained Earnings was $-55.86 Mil.
Pre-Tax Income was 0.297 + -0.39 + 1.043 + -2.82 = $-1.87 Mil.
Interest Expense was -0.65 + -0.64 + -0.656 + -0.947 = $-2.89 Mil.
Revenue was 5.702 + 8.009 + 7.569 + 8.825 = $30.11 Mil.
Market Cap (Today) was $1.56 Mil.
Total Liabilities was $44.38 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(34.803 - 43.971)/62.466
=-0.1468

X2=Retained Earnings/Total Assets
=-55.859/62.466
=-0.8942

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-1.87 - -2.893)/62.466
=0.0164

X4=Market Value Equity/Book Value of Total Liabilities
=Market Cap/Total Liabilities
=1.563/44.38
=0.0352

X5=Revenue/Total Assets
=30.105/62.466
=0.4819

The zones of discrimination were as such:

Distress Zones - 1.81 < Grey Zones < 2.99 - Safe Zones

Aoxing Pharmaceutical Co has a Altman Z-Score of -0.87 indicating it is in Distress Zones.

Study by Altman found that companies that are in Distress Zone have more than 80% of chances of bankruptcy in two years.

Frequently Asked Questions Learn more about Altman Z-Score →
What does a Altman Z-Score of -0.87 mean?
Aoxing Pharmaceutical Co (AOXG) has a Altman Z-Score of -0.87 as of Jul. 03, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Aoxing Pharmaceutical Co and its competitors.
Is Aoxing Pharmaceutical Co's Altman Z-Score too high?
Aoxing Pharmaceutical Co's current Altman Z-Score is -0.87.
How does Aoxing Pharmaceutical Co's Altman Z-Score compare to OWCP and BSPK?
Aoxing Pharmaceutical Co's Altman Z-Score of -0.87 can be compared against companies in the Diversified Financial Services industry. The industry median Altman Z-Score is 1.60. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Diversified Financial Services company?
The median Altman Z-Score among Diversified Financial Services companies is 1.60, based on 80 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Aoxing Pharmaceutical Co and its competitors. For the Diversified Financial Services industry, the median Altman Z-Score is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aoxing Pharmaceutical Co's current Altman Z-Score is -0.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aoxing Pharmaceutical Co stock overvalued right now?
Aoxing Pharmaceutical Co (AOXG) has a current Altman Z-Score of -0.87. The current Altman Z-Score is -0.87. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Aoxing Pharmaceutical Co (AOXG), the current Altman Z-Score is -0.87 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aoxing Pharmaceutical Co Business Description

Address Block 25, Flat F, 9th Floor, South Horizons, Apleichau, Hong Kong, HKG
Aoxing Pharmaceutical Co Inc does not have any business operations and is restructuring for a new business model and plans to acquire an operating company via reverse merger.